Japan

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Eisai Announces Updated Results of ENHANCE 1, Investigating HALAVEN plus KEYTRUDA in Patients with Metastatic Triple-Negative Breast Cancer

Lead Product(s): Eribulin Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

Results showed encouraging anticancer activity in both first-line and later lines, with an objective response rate (ORR) of 25.8% and 21%, respectively.

Daiichi Sankyo Co Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II

Lead Product(s): U3-1402

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

Preclinical and biomarker research data will be reported for U3-1402 (HER3 DXd ADC) in HER3 expressing cancers including combination with osimertinib in EGFR mutated NSCLC.

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib for Treatment of NSCLC Patients

Lead Product(s): Mobocertinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Breakthrough Therapy Designation is based on the overall response rate and the long-term benefit seen in patients who responded in a Ph 1/2 study evaluating the safety and efficacy of mobocertinib.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Eisai

Eisai Announces Updated Results of ENHANCE 1, Investigating HALAVEN plus KEYTRUDA in Patients with Metastatic Triple-Negative Breast Cancer

Daiichi Sankyo Co Ltd

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II

Takeda Pharmaceutical

Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib for Treatment of NSCLC Patients